George Kollias, Professor

George Kollias, Proffesor of Experimental Physiology, Director of Laboratory of Physiology

The main objective of our research is to understand the cellular and molecular mechanisms underlying immunological disease initiation, progression and chronicity, and to provide innovative solutions towards their diagnosis, prognosis and therapy. Towards that end, we use a unique collection of transgenic mouse models, conditional gene targeting, and state-of-the-art cellular and molecular technologies. We combine omics approaches and large-scale data analyses with in depth dissection of candidate gene function in vivo and in vitro, from human vs animal models, to discover causalities in the epigenetic, transcriptional and proteomic changes that occur in specific cell types of interest during disease course. Through the identification and validation of unexplored pathways, targets and biomarkers, we aim to introduce novel concepts towards disease prognosis, prevention and therapy.

Our research team is organized into five groups which are focused on specific organs and disease areas or on the development of preclinical therapeutic approaches:

  • Chronic Inflammatory Arthritis
  • Inflammatory Bowel Disease (IBD) and Cancer
  • Neuroinflammation and neuroimmune interactions
  • Dynamics of Mesenchymal Cells in Lymphoid Microenvironments
  • Drug Development Research

Our research is performed at the Department of Physiology of the Medical School of Athens, in collaboration with the laboratory of George Kollias at the Institute for Bioinnovation at the Biomedical Sciences Research Center “Alexander Fleming”, where George Kollias is an Associated Researcher.

 

Selected recent publications

  • Armaka M, Konstantopoulos D, Tzaferis C, Lavigne MD, Sakkou M, Liakos A, Sfikakis PP, Dimopoulos MA, Fousteri M, Kollias G. (2022) Single-cell multimodal analysis identifies common regulatory programs in synovial fibroblasts of rheumatoid arthritis patients and modeled TNF-driven arthritis. Genome Med. 2022 Jul 26;14(1):78. doi: 10.1186/s13073-022-01081-3. PMID: 35879783; PMCID: PMC9316748.
  • Prados A, Onder L, Cheng HW, Mörbe U, Lütge M, Gil-Cruz C, Perez-Shibayama C, Koliaraki V, Ludewig B, Kollias G. (2021) Fibroblastic reticular cell lineage convergence in Peyer’s patches governs intestinal immunity. Nat Immunol. 22(4):510-519.
  • Nanou A, Bourbouli M, Vetrano S, Schaeper U, Ley S, Kollias G. (2021) Endothelial Tpl2 regulates vascular barrier function via JNK-mediated degradation of claudin-5 promoting neuroinflammation or tumor metastasis. Cell Rep. 35(8):109168.
  • Roulis M, Kaklamanos A, Schernthanner M, Bielecki P, Zhao J, Kaffe E, Frommelt LS, Qu R, Knapp MS, Henriques A, Chalkidi N, Koliaraki V, Jiao J, Brewer JR, Bacher M, Blackburn HN, Zhao X, Breyer RM, Aidinis V, Jain D, Su B, Herschman HR,
  • Kluger Y, Kollias G, Flavell RA. (2020) Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche. Nature 580(7804) :524-529.
  • Koliaraki V, Chalkidi N, Henriques A, Tzaferis C, Polykratis A, Waisman A, Muller W, Hackam DJ, Pasparakis M, Kollias G. (2019) Innate Sensing through Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis. Cell Rep. 26(3):536-545.e4.
  • Henriques A, Koliaraki V, Kollias G. (2018) Mesenchymal MAPKAPK2/HSP27 drives intestinal carcinogenesis Proc Natl Acad Sci U S A. 115(24):E5546-E5555.
  • Armaka M, Ospelt C, Pasparakis M, Kollias G. (2018) The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts Nat Commun. 12;9(1):618.
  • Ntari L, Sakkou M, Chouvardas P, Mourouzis I, Prados A, Denis MC, Karagianni N, Pantos C, Kollias G. (2018) Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis Ann Rheum Dis. 77(6):926-934.

 

Recent reviews

  • Iliopoulou L, Kollias G. (2022) Harnessing murine models of Crohn’s disease ileitis to advance concepts of pathophysiology and treatment Mucosal Immunol. 15(1):10-26.
  • Koliaraki V, Prados A, Armaka M, Kollias G. (2020) The mesenchymal context in inflammation, immunity and cancer. Nat Immunol. 21(9): 974-982.
  • Koliaraki V, Henriques A, Prados A, Kollias G. (2020) Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme. J Exp Med. 217 (4):e20190457.
  • Koliaraki V, Pallangyo CK, Greten FR, Kollias G. (2017) Mesenchymal Cells in Colon Cancer Gastroenterology 152(5): 964-979.

Personnel

Doctoral students
Lida Iliopoulou, MSc
Christos Tzaferis, MSc (BioIT)

MSx students
Erifylli Lianopoulou
Polina Dimitrova

Management/Biocuration
Piyi Papadaki, PhD
Alexandra Boutla, PhD
Christina Chandras, PhD

 

Infrastructures/pMedGR
Maria Sakkou, PhD
Kelly Vetsika, PhD
Panagiotis Lembessis, PhD
Kleio Verrou, ΜSc (ΒioIT)
Menelaos Manoloukos, ΜSc

Secretariat MSc Molecular Biomedicine
Jean Gouzi, PhD

 

Recent funding

Project TitleFunderBudgetDurationRole 
BecomingCausal – Contextual specification of fibroblast-driven causalities in chronic intestinal inflammation and fibrosis (#101055093 )European Research Council2.411.000€2022-2027Principal Investigator
SingleOut – Understanding the heterogeneity of the tumor microenvironment at the single cell level
(Grant ID: 3780)
ΕΛΙΔΕΚ1.440.000€2021-2024Principal Investigator
Strengthening BSRC Fleming’s Research Infrastructures to foster regional development in the area of drug development and diagnostic tools
(Grant ID: 5063821)
Επιχ. Πρόγραμμα ΑΤΤΙΚΗ, ΕΣΠΑ 2014-2020, ΕΤΠΑ745.900€2021-2023Principal Investigator
Drug.ART – Development of small molecule inhibitors for the treatment of chronic inflammatory diseases, targeting the activation of pathogenic fibroblasts
(Grant ID: 5067529)
ΕΠΑΝΕΚ, ΕΣΠΑ 2014-2020, ΕΤΠΑ672.300€2020-2022Coordinator and Principal Investigator
EOSC-Life – Providing an open collaborative space for digital biology in EuropeEuropean Commission, Horizon 202067.500€2019-2023Participant
InfrafrontierGR/Phenotypos – The Greek Research Infrastructure for molecular and behavioral phenotyping of model organisms for chronic degenerative diseases
(Grant ID: 5002135)
ΕΠΑΝΕΚ, ΕΣΠΑ 2014-2020, ΕΤΠΑ1.770.000€2018-2021Coordinator and Principal Investigator
pMedGR – The Greek Research Infrastructure for Personalised Medicine
(Grant ID: 5002802)
ΕΠΑΝΕΚ, ΕΣΠΑ 2014-2020, ΕΤΠΑ650.000€2018-2021Member of Management Board, PI Fleming
Infrafrontier2020 – Mouse model generation using state of the art technologies incl. CRISPR/Cas9European Commission, Horizon 2020107.800€2017-2021Participant
MCs-inTEST – Mesenchymal Cells of the Lamina Propria in Intestinal Epithelial and Immunological Homeostasis
(Grant ID: ERC-2013-AdG-340217)
European Research Council2.590.000€2014-2019Principal Investigator